BridGene Biosciences Announces Dosing of First Patient in Phase 1 Study Evaluating Novel TEAD Inhibitor BGC515 in Advanced Solid Tumors
SAN JOSE, Calif., June 28, 2024 /PRNewswire/ -- BridGene Biosciences, Inc., a leader in developing covalent small molecule drugs for traditional…
